Talfirastide(Talfirastide) - 药物靶点：Mas receptor_在研适应症：缺血性卒中，DMD相关的扩张型心肌病，杜氏肌营养不良症_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Angiontensin(1-7)、Angiotensin (1-7)、Angiotensin I (1-7)

+ [4]

靶点

Mas receptor

作用机制

Mas receptor激动剂(原癌基因 Mas激动剂)

治疗领域

神经系统疾病心血管疾病遗传病与畸形+ [4]

在研适应症

缺血性卒中DMD相关的扩张型心肌病杜氏肌营养不良症+ [6]

非在研适应症

急性白血病急性淋巴细胞白血病急性髓性白血病+ [14]

原研机构

Tarix Orphan LLC

在研机构

Constant Therapeutics LLC

US Biotest, Inc.

Tarix Orphan LLC

非在研机构

Tarix Pharmaceuticals Ltd.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C41H62N12O11

InChIKeyPVHLMTREZMEJCG-GDTLVBQBSA-N

CAS号51833-78-4

关联

25

项与 Talfirastide 相关的临床试验

NCT06482853

/ Recruiting早期临床1期IIT

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.

开始日期2024-12-01

申办/合作机构

Hershey Medical Center

[+1]

NCT06282965

/ Recruiting临床1/2期IIT

A Randomized, Double-blind, Placebo Controlled Study of the Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury (TBI)

The goal of this clinical trial is to test the safety of the drug Angiotensin (1-7) and learn whether it works well as a treatment in people who have suffered a moderate to severe traumatic brain injury (TBI).
The main questions this trial aims to answer are:
* Is Angiotensin (1-7) safe?
* Does Angiotensin (1-7) improve mental functioning and reduce physical signs of brain damage in people who have suffered a moderate to severe TBI?
Participants will:
* Complete 21 days of study treatment consisting of a once-daily injection.
* Provide blood samples.
* Undergo two magnetic resonance imaging (MRI) scans of the brain.
* Complete specific tasks and questionnaires that allow researchers to evaluate the participant's brain and psychological functioning.
Researchers will compare three groups: two groups that receive different doses of Angiotensin (1-7) and one group that receives a look-alike treatment with no active drug. This will allow researchers to see if the drug has any negative effects and whether it improves mental functioning and physical signs of brain damage after a TBI.

开始日期2024-05-28

申办/合作机构

University of Arizona

RBR-3bhkdg2

/ RecruitingN/A

Angiotensin formulations-(1-7) its actions on physical performance and injury repair muscular

开始日期2024-03-28

申办/合作机构

Universidade Federal de Ouro Preto

100 项与 Talfirastide 相关的临床结果

登录后查看更多信息

100 项与 Talfirastide 相关的转化医学

登录后查看更多信息

100 项与 Talfirastide 相关的专利（医药）

登录后查看更多信息

660

项与 Talfirastide 相关的文献（医药）

2024-12-05·Antimicrobial Agents and Chemotherapy

Intranasal liposomal angiotensin-(1-7) administration reduces inflammation and viral load in the lungs during SARS-CoV-2 infection in K18-hACE2 transgenic mice

Article

作者: Figueiredo, Maria Marta ; Costa, Pedro Augusto Carvalho ; Mendes, Sabrina ; Fernandez, Clara Couto ; dos Santos, Robson Augusto Souza ; Teixeira, Mauro Martins ; Guimarães, Lays Cordeiro ; Frézard, Frédéric ; Guimarães, Pedro Pires Goulart

ABSTRACTTo effectively reduce the health impact of coronavirus disease (COVID-19), it is essential to adopt comprehensive strategies to protect individuals from severe acute respiratory syndrome. In that sense, much effort has been devoted to the discovery and repurposing of effective antiviral and anti-inflammatory molecules. The endogenous peptide angiotensin-(1-7) [Ang-(1-7)] has been recently proposed as a promising anti-inflammatory agent to control respiratory infections. Liposomes also emerged as a safe and effective drug carrier system for local drug delivery to the lungs. In this context, the aim of this study was to develop a liposomal formulation of Ang-(1-7) [LAng (1-7)] and investigate its impact on animal survival as well as its antiviral and anti-inflammatory efficacies after intranasal administration in transgenic K18-hACE2 mice infected with SARS-CoV-2. The liposomal formulation was prepared by the ethanol injection method, exhibiting a mean diameter of 100 nm and a polydispersity index of 0.1. Following treatment of infected mice every 12 hours for 5 days, LAng (1-7) extended animal survival compared to the control groups that received either empty liposomes, free Ang-(1-7), or phosphate-buffered saline. Furthermore, the treatment with LAng (1-7) significantly decreased the viral load, as well as IL-6 and tumor necrosis factor levels in the lungs. Conventional treatment with remdesivir by parenteral route used as a positive control promoted similar effects, leading to improved survival rates and reduced viral load in the lungs without significant effects on IL-6 level. In conclusion, liposomal Ang-(1-7) emerges as a promising formulation to improve the treatment and decrease the severity of respiratory infections, such as COVID-19.

2024-11-01·Analytical and Bioanalytical Chemistry

Collision cross sections of large positive fullerene molecular ions and their use as ion mobility calibrants in trapped ion mobility mass spectrometry

Article

作者: Gross, Jürgen H ; Oppenländer, Tobias ; Gross, Jürgen H.

AbstractPositive-ion laser desorption/ionization (LDI) of fullerenes contained in soot as produced by the Krätschmer-Huffman process delivers a wide range of fullerene molecular ions from C56+• to above C300+•. Here, the collision cross section (CCS) values of those fullerene molecular ions are determined using a trapped ion mobility-quadrupole-time-of-flight (TIMS-Q-TOF) instrument. While CCS values in the range from C60+• to C96+• are already known with high accuracy, those of ions from C98+• onward had yet to be determined. The fullerene molecular ions covered in this work have CCS values from about 200 to 440 Å2. The fullerene molecular ion series is evenly spaced at C2 differences in composition, and thus, small CCS differences of just 2.2–3.5 Å2 were determined across the entire range. Fullerene M+• ions may be employed as mobility calibrants, in particular, when very narrow 1/K0 ranges are being analyzed to achieve high TIMS resolving power. In addition, due to the simple elemental composition, M+• ions of fullerenes could also serve for mass calibration. This study describes the determination of CCS values of fullerene molecular ions from C56+• to C240+• and the application of ions from C56+• to C220+• to calibrate the ion mobility scale of a Bruker timsTOFflex instrument in any combination of LDI, matrix-assisted laser desorption/ionization (MALDI), and electrospray ionization (ESI) modes in the CCS range from about 200 to 420 Å2. This use was exemplified along with ions from Agilent Tune Mix, leucine-enkephalin, angiotensin I, angiotensin II, and substance P.Graphical Abstract

2024-11-01·Experimental Neurology

The angiotensin (1–7) glycopeptide PNA5 improves cognition in a chronic progressive mouse model of Parkinson's disease through modulation of neuroinflammation

Article

作者: Doyle, Kristian P ; Bartlett, Mitchell J ; Falk, Torsten ; Mota, Jesus A ; Bernard, Kelsey ; Heien, M Leandro ; Hay, Meredith ; Corenblum, Mandi J ; Polt, Robin ; Wene, Paige ; Saez, Juben L ; Madhavan, Lalitha

Cognitive decline in Parkinson's Disease (PD) is a prevalent and undertreated aspect of disease. Currently, no therapeutics adequately improve this aspect of disease. It has been previously shown that MAS receptor agonism via the glycosylated Angiotensin (1-7) peptide, PNA5, effectively reduces cognitive decline in models of vascular contributions to cognitive impairment and dementia (VCID). PNA5 has a brain/plasma ratio of 0.255 indicating good brain penetration. The goal of the present study was to determine if (1) systemic administration of PNA5 rescued cognitive decline in a mouse model of PD, and (2) if improvements in cognitive status could be correlated with changes to histopathological or blood plasma-based changes. Mice over-expressing human, wild-type α-synuclein (αSyn) under the Thy1 promoter (Thy1-αSyn mice, "line 61") were used as a model of PD with cognitive decline. Thy1-αSyn mice were treated with a systemic dose of PNA5, or saline (1 mg/kg/day) beginning at 4 months of age and underwent behavioral testing at 6 months, compared to WT. Subsequently, mice brains were analyzed for changes to brain pathology, and blood plasma was examined with a Multiplex Immunoassay for peripheral cytokine changes. Treatment with PNA5 reversed cognitive dysfunction measured by Novel Object Recognition and spontaneous alteration in a Y-maze in Thy1-αSyn mice. PNA5 treatment was specific to cognitive deficits, as fine-motor disturbances were unchanged. Enhanced cognition was associated with decreases in hippocampal inflammation and reductions in circulating levels of Macrophage Induced Protein (MIP-1β). Additionally, neuronal loss was blunted within the CA3 hippocampal region of PNA5-treated αsyn mice. These data reveal that PNA5 treatment reduces cognitive dysfunction in a mouse model of PD. These changes are associated with decreased MIP-1β levels in plasma identifying a candidate biomarker for target engagement. Thus, PNA5 treatment could potentially fill the therapeutic gap for cognitive decline in PD.

2

项与 Talfirastide 相关的新闻（医药）

2024-03-04

·PRNewswire

Constant Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of TXA127 in Duchenne Muscular Dystrophy-Associated Cardiomyopathy

BOSTON, March 4, 2024 /PRNewswire/ -- Constant Therapeutics LLC, a biopharmaceutical company focused on the development of treatments impacting the Alternative Renin-Angiotensin System, today announced that the first patient was dosed March 3, 2024, in the Company's phase 2 clinical trial of TXA127, the Company's lead peptide product under development as a potential treatment for Duchenne Muscular Dystrophy-associated (DMD-associated) Cardiomyopathy. The phase 2 trial is an open-label, multi-center trial designed to evaluate the safety and efficacy in non-ambulatory patients with DMD-associated Cardiomyopathy who are 16 years and older and who are receiving systemic glucocorticoids. Patients will receive 6 months of treatment and have the option to enter a 12-month extension study. The study is being conducted in Israel at Sheba Medical Center and Hadassah Medical Center and is expected to enroll 10 patients. "This is a significant milestone for Constant and for the DMD community," said Rick Franklin, CEO of Constant Therapeutics. "There are few treatments for DMD patients with cardiomyopathy, and heart failure is a leading cause of death in this disease. We are excited to initiate this carefully designed trial, and we look forward to sharing the data with the DMD community upon completion of the trial." About Constant Therapeutics LLC Constant Therapeutics LLC is a private biopharmaceutical company focused on the development of treatments that effect the Alternative Renin-Angiotensin System. The lead compound, TXA127, is a pharmaceutical formulation of the naturally occurring peptide Angiotensin (1-7) and is being developed for the treatment of stroke recovery and DMD-associated Cardiomyopathy. For more information on Constant Therapeutics, please visit our website at . About TXA127 TXA127 is a pharmaceutical formulation of the naturally occurring human peptide angiotensin-(1‐7). In addition to its specific effects in cardiac dysfunction, TXA127 has shown therapeutic activity in animal models of chronic stroke, Duchenne Muscular Dystrophy (DMD), Limb‐Girdle Muscular Dystrophy (LGMD), Congenital Muscular Dystrophy (MDC1A), Marfan Syndrome and Epidermolysis Bullosa. Contact: [email protected] +1-617-245-0289 SOURCE Constant Therapeutics

临床2期

2024-01-09

·PRNewswire

Constant Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of TXA127 in Ischemic Stroke Recovery

BOSTON, Jan. 9, 2024 /PRNewswire/ -- Constant Therapeutics LLC, a biopharmaceutical company focused on the development of treatments impacting the Alternative Renin-Angiotensin System, today announced that the first patient has been dosed in the Company's phase 2 clinical trial of TXA127, the Company's lead peptide product under development as a potential treatment for ischemic stroke recovery. The phase 2 trial is a randomized, placebo-controlled, double-blind, hybrid decentralized study designed to evaluate the safety and efficacy in ischemic stroke patients who are 18 to 85 years old and who are 6 to 24 months post stroke event. Patients will receive 3 months of treatment. The study is being conducted in Israel at Sheba Medical Center in collaboration with Sabar Health for the home visits, and it is expected to enroll 50 patients. "There are no drugs available to treat chronic stroke, but the design and logistics of clinical trials in these patients is particularly difficult. We are fortunate to have been able to put together the infrastructure needed, with the participation of Sabar Health and Sheba Medical Center. This unique combination will allow us to test TXA127 for this important unmet medical need," said Rick Franklin, CEO of Constant Therapeutics." About Constant Therapeutics LLC Constant Therapeutics LLC is a private biopharmaceutical company focused on the development of treatments that effect the Alternative Renin-Angiotensin System. The lead compound, TXA127, is a pharmaceutical formulation of the naturally occurring peptide Angiotensin (1-7) and is being developed for the treatment of stroke recovery and DMD-associated Cardiomyopathy. For more information on Constant Therapeutics, please visit our website at . About TXA127 TXA127 is a pharmaceutical formulation of the naturally occurring human peptide angiotensin-(1‐7). In addition to its specific effects in ischemic stroke, TXA127 has shown therapeutic activity in animal models Duchenne Muscular Dystrophy (DMD), Limb‐Girdle Muscular Dystrophy (LGMD), Congenital Muscular Dystrophy (MDC1A), Marfan Syndrome and Epidermolysis Bullosa. Contact: [email protected] +1-617-245-0289 SOURCE Constant Therapeutics

临床2期

100 项与 Talfirastide 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11720

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
杜氏肌营养不良症	临床2期	-	Tarix Orphan LLC	-
代谢性疾病	临床1期	美国	Tarix Pharmaceuticals Ltd.	2012-03-01
霍奇金淋巴瘤	临床1期	美国	Tarix Pharmaceuticals Ltd.	2010-06-01
霍奇金淋巴瘤	临床1期	美国	Constant Therapeutics LLC	2010-06-01
多发性骨髓瘤	临床1期	美国	Tarix Pharmaceuticals Ltd.	2010-06-01
多发性骨髓瘤	临床1期	美国	Constant Therapeutics LLC	2010-06-01
贫血	临床前	美国	Tarix Pharmaceuticals Ltd.	2008-10-01
淋巴细胞减少	临床前	美国	Tarix Pharmaceuticals Ltd.	2008-10-01
中性粒细胞减少	临床前	美国	Tarix Pharmaceuticals Ltd.	2008-10-01
血小板减少症	临床前	美国	Tarix Pharmaceuticals Ltd.	2008-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04924660 (Pubmed \| JAMA)	临床2/3期	新型冠状病毒感染	-	TXA-127	願積遞製廠築積壓夢構(築壓製鹹襯鹹夢鬱衊獵) = 窪膚願蓋鏇蓋鹽窪鹽糧觸獵遞顧網壓醖艱鏇膚 (夢鹹繭膚觸範製觸壓壓 )	-	2023-04-11
				TRV-027	願積遞製廠築積壓夢構(築壓製鹹襯鹹夢鬱衊獵) = 繭窪鏇膚淵鏇糧製襯餘觸獵遞顧網壓醖艱鏇膚 (夢鹹繭膚觸範製觸壓壓 )
NCT04401423 (CTgov)	临床2期	新型冠状病毒感染	22	TXA127 (TXA127)	糧夢構膚餘衊夢糧範齋(製淵鏇網鑰齋簾積襯襯) = 窪糧鹽憲簾齋築壓願夢積範鑰蓋築積獵選廠願 (蓋鹽餘簾襯鬱網鑰膚鏇, 醖網襯遞積繭築膚醖築 ~ 齋簾襯製築繭鑰醖鏇獵) 更多	-	2022-07-27
				Placebo (Placebo)	糧夢構膚餘衊夢糧範齋(製淵鏇網鑰齋簾積襯襯) = 製構鹹構壓襯齋壓衊鑰積範鑰蓋築積獵選廠願 (蓋鹽餘簾襯鬱網鑰膚鏇, 範鏇顧獵觸窪餘憲簾壓 ~ 膚糧淵遞網遞遞淵憲夢) 更多
ESH2021	N/A	-	-	Angiotensin II (ANG)	範鬱夢觸鹹廠簾蓋壓艱(鹽壓淵簾繭鹽鬱艱鏇餘) = 壓憲獵願衊鹹選選廠鏇築願鏇糧製獵鏇選膚繭 (膚醖鑰蓋憲齋襯繭築糧 ) 更多	-	2021-04-01
				Combination LOS+ANG	觸範膚醖鹹醖構壓蓋衊(鑰淵鹽夢願遞醖餘膚襯) = 願壓膚選顧餘壓選鏇廠膚製餘艱醖顧觸鏇選範 (網齋餘壓餘壓構簾膚遞 )
ASN2020	N/A	急性肾损伤 Angiotensin 1-7	27	Angiotensin 1-7 (Angiotensin II)	選鏇夢糧壓鹽衊顧淵繭(壓構憲範餘獵壓襯繭蓋) = 鬱蓋醖廠鹹艱廠鬱糧壓築獵窪齋觸廠齋壓窪鹽 (製窪簾築餘顧膚糧繭觸, 0.93 ~ 1.0)	积极	2020-10-19
ASN2020	临床2期	肿瘤 c-MET	-	ANG-3777 2 mg/kg	(餘窪齋顧衊鏇鏇廠廠鏇) = Overall survival did not differ in animals treated with ANG-3777 vs vehicle 窪窪鑰廠積膚獵淵窪鬱 (積蓋憲願遞顧鑰鏇構糧 ) 更多	积极	2020-10-19
				Vehicle (dimethyl sulfoxide)
ISC2014	N/A	脑卒中	24	dH2O	鑰鏇築廠顧廠鹽憲積鬱(膚觸簾遞鬱齋餘鬱顧築) = 壓醖願襯鏇膚獵壓膚鬱遞鑰獵壓壓簾糧齋憲顧 (鏇鬱淵鹽鏇衊觸製鹹壓 )	积极	2014-02-01
				HPβCD/Ang-(1-7)	鑰鏇築廠顧廠鹽憲積鬱(膚觸簾遞鬱齋餘鬱顧築) = 膚餘選廠夢製鹹構鑰網遞鑰獵壓壓簾糧齋憲顧 (鏇鬱淵鹽鏇衊觸製鹹壓 )
NCT01553539 (CTgov)	临床2期	骨癌 \| 软骨肉瘤 \| 复发性骨肉瘤 \| 转移性软组织肉瘤 \| 复发性子宫肉瘤 \| 转移性骨肉瘤 \| 肾透明细胞肉瘤	20	laboratory biomarker analysis+therapeutic angiotensin-(1-7)	鏇鹹艱齋衊鹹範鹹衊齋(廠鏇鹹製鏇獵築齋衊鏇) = 廠鬱遞獵餘膚鏇餘遞襯製憲鹹鏇襯網簾築觸鹽 (網糧積選構遞願範構鑰, 範選築夢糧範鬱願衊構 ~ 醖鹹廠鏇憲蓋網顧顧糧) 更多	-	2014-01-30
NCT00771810 (CTgov)	临床2期	贫血 \| 血小板减少症 \| 中性粒细胞减少 \| 淋巴细胞减少	34	Placebo (Placebo)	艱壓鹽餘齋膚鬱窪鹹蓋(簾製範醖窪醖壓簾築襯) = 襯製壓襯願築窪簾簾遞窪選繭膚衊襯蓋淵衊蓋 (壓積繭構鬱膚網襯艱網, 廠鹹醖製醖鹽壓憲夢襯 ~ 夢淵壓膚齋糧鹽製糧夢) 更多	-	2013-06-07
				TXA127 (TXA127 100 ug/kg)	艱壓鹽餘齋膚鬱窪鹹蓋(簾製範醖窪醖壓簾築襯) = 壓膚願築艱襯膚繭夢夢窪選繭膚衊襯蓋淵衊蓋 (壓積繭構鬱膚網襯艱網, 願艱膚襯鑰選窪遞願製 ~ 廠遞鹽膚蓋築蓋遞襯醖) 更多
5C.07 (ESH2010)	N/A	norepinephrine	-	Angiotensin-(1-7)	願範淵鹹蓋壓壓鑰網膚(築餘鹽網膚遞願鑰齋鹽) = 衊衊衊築衊夢鑰範鏇遞鏇壓壓積簾艱膚鏇淵觸 (憲襯獵範積鹽構糧蓋鹽 )	积极	2010-06-01
NCT00471562 (Pubmed \| Clin Cancer Res)	临床1期	转移性实体瘤 \| 晚期恶性实体瘤	18	Angiotensin-(1-7)	(築鑰淵鏇醖構壓顧願窪) = 蓋築獵範築淵廠醖淵鬱窪鑰廠製淵餘蓋蓋夢窪 (淵壓網襯窪夢積糧觸壓 )	-	2009-12-01